Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

209.38
-1.2500-0.59%
Volume:176.42K
Turnover:37.09M
Market Cap:10.97B
PE:-55.56
High:211.65
Open:210.63
Low:208.01
Close:210.63
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.52
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:131.66
PE(LYR):-56.86

Loading ...

Axsome settles all Sunosi patent litigation, sets generic entry for 2040

Reuters
·
Jun 03

Axsome Therapeutics - Resolves All Patent Litigation Related to Sunosi

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics - Five Companies Granted Right to Sell Generic Sunosi From 2040, Subject to FDA Approval

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics - Enters Settlement Agreement With First-to-File Generic Applicant for Sunosi

THOMSON REUTERS
·
Jun 03

Axsome Therapeutics director Mark Coleman disposes of common shares worth $4.06 million

Reuters
·
Jun 03

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

GlobeNewswire
·
Jun 01

Axsome Therapeutics (AXSM) Valuation Check After Strong Recent Share Price Momentum

Simply Wall St.
·
May 31

Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says

MT Newswires Live
·
May 28

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 27

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

GlobeNewswire
·
May 26

Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?

Simply Wall St.
·
May 14

Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)

TIPRANKS
·
May 11

Axsome Therapeutics Recognizes Mental Health Month

GlobeNewswire
·
May 07

Axsome Therapeutics (AXSM) Q1 Loss Widening To US$64.5 Million Tests Profitability Narratives

Simply Wall St.
·
May 06

Axsome COO Mark Jacobson disposes of common shares worth $1.08 million

Reuters
·
May 06

B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating

MT Newswires Live
·
May 05

Axsome Therapeutics Inc : B. Riley Raises Target Price to $300.00 From $230.00

THOMSON REUTERS
·
May 05

Axsome Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
May 05

Axsome Therapeutics to present at BofA Securities Health Care Conference

Reuters
·
May 05

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and Merck & Company (MRK)

TIPRANKS
·
May 05